Skip to main content

Table 1 Comparisons of characteristics between survivors and non-survivors in patients with HBV-ACLF

From: A novel predictive model based on inflammatory markers to assess the prognosis of patients with HBV-related acute-on-chronic liver failure: a retrospective cohort study

Variables Total patients
(n = 421) 		Survivors
(n = 222) 		Non-survivors
(n = 199) 		P value
Age (years) 47.93 ± 11.40 48.10 ± 11.20 47.75 ± 11.64 0.735
Gender (M/F) 365/56 195/27 170/29 0.468
Cirrhosis (%) 299(71.02%) 159(71.62) 140(70.35) 0.744
Bacterial infections 307(72.92%) 145(65.32) 162(81.41) < 0.001
HBV-DNA (107IU/mL) 1.53 ± 4.85 1.89 ± 5.16 1.17 ± 4.53 0.139
HbeAg(+) n (%) 116(27.55) 67(30.18) 49(24.62) 0.203
ALT(U/L) 228(63.20,847.60) 258.75(52.65,1000.33) 198.20(74.80,755.10) 0.532
AST(U/L) 223.40(103.95,641.90) 254.10(94.63,254.10) 206.10(110.10,511.20) 0.477
TBIL(μmol/L) 323.39 ± 165.69 236.35 ± 118.55 420.49 ± 156.77 < 0.001
ALB(g/L) 29.09 ± 5.57 29.33 ± 5.81 28.82 ± 5.30 0.348
γ-GGT(U/L) 85.40(48.5143.00) 79.35(48.45,157,13) 86.30(48.50,126.80) 0.719
Cr (μmol/L) 69.30(57.25,87.90) 68.45(57.90,79.78) 70.1(55.6106.8) 0.002
Cyst-c(mg/L) 1.21(0.92,1.756) 1.11(0.89,1.55) 1.38(0.93,1.38) 0.001
K+(mmol/L) 3.97 ± 0.65 3.99 ± 0.60 3.95 ± 0.70 0.510
Na+(mmol/L) 135.46 ± 5.71 135.79 ± 5.70 134.86 ± 5.66 0.042
PT(s) 24.90(21.35,29.30) 23.70(21.38,27.88) 26.40(21.3,31.7) 0.271
INR 2.25(1.86,2.76) 2.12(1.86,2.62) 2.40(1.85,3.16) < 0.001
PTA (%) 34.11 ± 10.60 35.79 ± 9.49 32.23 ± 11.45 0.001
WBC (109/L) 6.43(4.72,9.13) 5.83(424,7.86) 7.56(5.45,10.71) < 0.001
Neutrophils (109/L) 4.65(3.11,7.21) 3.92(2.88,5.80) 5.98(3.82,8.52) < 0.001
Lymphocytes(109/L) 0.96(0.66,1.33) 1.03(0.71,1.41) 0.89(0.61,1.28) 0.030
Monocytes(109/L) 0.61(0.40,0.90) 0.54(0.37,0.77) 0.70(0.45,1.04) < 0.001
RDW (%) 15.90(14.35,18.45) 15.00(14.0,17.03) 16.82(15.00,20.70) < 0.001
PLT (109/L) 86.00 (58.0,126.0) 82.00(53.0,125.0) 89.00(64.0,89.0) 0.155
MPV(FL) 11.75 ± 1.53 11.82 ± 1.48 11.67 ± 1.58 0.312
NLR 4.84(3.19,8.09) 4.00(2.57,6.10) 6.31(4.19,10.25) < 0.001
GPR 0.97(0.59,1.69) 0.98(0.62,1.69) 0.95(0.51,1.70) 0.253
MLR 0.64(0.42,0.94) 0.53(0.38,0.74) 0.77(0.52,1.10) < 0.001
RPR 0.19(0.12,0.30) 0.18(0.12,0.32) 0.19(0.14,0.30) 0.490
MPR 0.14(0.09,0.20) 0.15(0.10,0.22) 0.13(0.09,0.19) 0.103
PNI 34.10(30.20,38.33) 34.98(30.33,39.14) 33.65(30.10,37.30) 0.060
PLR 91.03(62.66,127.75) 85.20(57.45,118.76) 102.15(70.37,144.12) 0.001
RLR 16.70(11.66,25.96) 15.68(10.66,22.65) 20.57(13.25,30.00) < 0.001
PCT (μg/L) 0.88(0.48,3.31) 0.79(0.44,2.88) 0.99(0.54,3.52) 0.064
MELD SCORE 25.05 ± 6.75 22.47 ± 4.67 27.94 ± 7.52 < 0.001
MELD-Na 24.43 ± 12.48 20.36 ± 11.09 28.98 ± 12.41 < 0.001
CTP, n (%)     < 0.001
 5–6 1(0.24) 1(0.45) 0(0)  
 7–9 69(16.39) 56(25.21) 13(6.53)  
  ≥ 10 351(83.37) 165(74.32) 186(93.46)  
HE, n (%)     0.005
 Stage 0 332(78.86) 184(82.90) 148(74.37)  
 Stage 1 14(3.33) 9(4.10) 5(2.51)  
 Stage 2 23(5.46) 12(5.4) 11(5.53)  
 Stage 3 28(6.65) 13(5.9) 15(7.54)  
 Stage 4 24(5.70) 4(1.8) 20(10.05)  
Antiviral therapy, n (%)     0.841
 ETV 339(80.52) 175(78.83) 164(82.41)  
 TDF 56(13.30) 32(14.41) 24(12.06)  
 LAM 10(2.38) 5(2.25) 5(2.51)  
 ADV 12(3.09) 7(3.15) 5(2.51)  
 ADV + LAM 4(0.95) 3(1.35) 1(0.50)  
  1. ALT alanine aminotransferase, AST aspartate aminotransferase, TBIL total bilirubin, ALB albumin, γ-GGT gamma-glutamyl transpeptidase, Cr creatinine, Cyst-c cystatin c, Serum k+ serum potassium, Serum Na+ serum sodium, PT prothrombin time, INR international normalized ratio, PTA prothrombin activity, WBC white blood cell count, RBC red blood cells, HGB hemoglobin, PLT platelet, RDW red blood cell distribution width, NLR neutrophil/lymphocyte ratio, MLR monocyte/lymphocyte ratio, PLR platelet/lymphocyte ratio, RPR RDW/platelet ratio, GPR gamma-glutamyl transpeptidase/platelet ratio, MPV mean platelet volume, RLR RDW/lymphocyte ratio, PNI prognostic nutritional index, MPR MPV/platelet ratio, PCT procalcitonin, MELD SCORE model for end-stage liver disease score, CTP child-Turcotte Pugh score, MELD-Na MELD-sodium score, HE hepatic encephalopathy, ETV entecavir, TDF tenofovirdisoproxil, LAM lamivudine, ADV adefovir dipivoxil
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us

\